{"id":"W3215895013","doi":"10.1093/immadv/ltab022","title":"A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes","year":2021,"lang":"en","type":"article","venue":"Immunotherapy Advances","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Children's Hospital; University of British Columbia; University of Calgary","funders":"Breakthrough T1D Canada; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Versus Arthritis; Diabetes UK; Leona M. and Harry B. Helmsley Charitable Trust; National Institute for Health and Care Research; Immune Tolerance Network; Innovative Medicines Initiative; BC Children's Hospital","keywords":"Medicine; Dosing; Internal medicine; Cohort; Maintenance therapy; Type 1 diabetes; Adverse effect; Type 2 diabetes; Clinical endpoint; Cmax; Gastroenterology; Immunology; Diabetes mellitus; Pharmacokinetics; Endocrinology; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002801217,0.0009923928,0.001404016,0.0003306516,0.0005495159,0.000612493,0.0005808962,0.0009947584,0.002981347],"category_scores_gemma":[0.001861767,0.000521557,0.0008768702,0.0002873314,0.0007204665,0.000765253,0.000350861,0.001837526,0.000706516],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006603147,"about_ca_system_score_gemma":0.001622228,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008425203,"about_ca_topic_score_gemma":0.002610943,"domain_scores_codex":[0.9990119,0.0005654963,0.00006225892,0.0001400512,0.0001116228,0.0001087369],"domain_scores_gemma":[0.9986634,0.0002599165,0.000330824,0.000117817,0.0001395583,0.0004885141],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7201509,0.1160774,0.03859989,0.0008957016,0.001522621,0.0003070973,0.0006647421,0.0007520503,0.04269553,0.0001166756,0.002169156,0.07604821],"study_design_scores_gemma":[0.4210103,0.5210447,0.05129014,0.00003908709,0.0006315292,0.0002602117,0.000116098,0.0005506355,0.002529249,0.0001128116,0.002386905,0.00002828529],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942136,0.0008435089,0.0004426707,0.0001921942,0.00005685847,0.003028261,0.0005926131,0.00003688936,0.0005933408],"genre_scores_gemma":[0.9908635,0.0007190766,0.00221484,0.0008226246,0.000141825,0.003368135,0.0007413279,0.00001660211,0.001111998],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002981347,"threshold_uncertainty_score":0.0148145,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01257137853055862,"score_gpt":0.3053642460621322,"score_spread":0.2927928675315736,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}